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Fructose operonFructose-1-phosphate (F1P) is the preferred effector of the catabolite repressor/activator (Cra)
protein of the soil bacterium Pseudomonas putida but its ability to bind other metabolic intermediates
in vivo is unclear. The Cra protein of this microorganism (CraPP) was submitted tomobility shift assays
with target DNA sequences (the PfruB promoter) and candidate effectors fructose-1,6-bisphosphate
(FBP), glucose 6-phosphate (G6P), and fructose-6-phosphate (F6P). 1 mM F1P was sufﬁcient to release
most of the Cra protein from its operators but more than 10mM of FBP or G6P was required to free
the same complex. However, isothermal titration microcalorimetry failed to expose any speciﬁc inter-
action between CraPP and FBP or G6P. To solve this paradox, transcriptional activity of a PfruB-lacZ
fusion was measured in wild-type and DfruB cells growing on substrates that change the intracellular
concentrations of F1P and FBP. The data indicated that PfruB activity was stimulated by fructose but
not by glucose or succinate. This suggested that CraPP represses expression in vivo of the cognate
fruBKA operon in a fashion dependent just on F1P, ruling out any other physiological effector.
Molecular docking and dynamic simulations of the Cra-agonist interaction indicated that both
metabolites can bind the repressor, but the breach in the relative afﬁnity of CraPP for F1P vs FBP is
three orders of magnitude larger than the equivalent distance in the Escherichia coli protein. This
assigns the Cra protein of P. putida the sole role of transducing the presence of fructose in themedium
into a variety of direct and indirect physiological responses.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The enterobacterial catabolite repressor/activator (Cra) protein
is a pleiotropic regulator that controls expression of a large number
of metabolic genes in response to the ﬂux of central glycolytic
intermediates [1,2]. In particular, the Cra protein of Escherichia coli
(CraEC) represses transcription of genes such as fruB, pfkA, pykA,
pykF, acnB, edd, eda, mtlADR and gapB [1,3–6] while stimulatingexpression of others e.g., ppsA, fbp, pckA, acnA, icd, aceA, and aceB
[1,7–10]. The Cra protein was ﬁrst identiﬁed as repressor of the
fructose operon (fruBKA; [11]) thereby the earlier (and synony-
mous) name FruR. But, which is the metabolite sensed by Cra,
the levels of which report on the status of carbon metabolic ﬂuxes?
The ﬁrst hints to answer this question came from a number of
studies published in the 90s demonstrating that the effects of Cra
on transcription can be counteracted in vitro by lM levels of fruc-
tose-1-phosphate (F1P) as well as by concentrations of fructose-
1,6-bisphosphate (FBP) above 5 mM [1,4,11,12]. However, the
response of CraEC to high levels of FBP has been a matter of contro-
versy in the literature, as some studies have suggested that in vitro
assays of the regulator to this effector could be misleading due to
contamination with F1P [11]. In contrast, other Authors claim that
FBP is a genuine CraEC effector [4,13] and that the glycolytic ﬂux of
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dently of the carbon source used [13,14]. However, the functions
of Cra in other species are less clear, as the regulator is also present
in bacteria that hardly adopt a metabolic regime (i.e., no glycolytic
activity) that produces high FBP levels.
The metabolically versatile soil bacterium Pseudomonas putida
is one of such cases. In one hand, the central biochemical routes
generate F1P only when cells grow on fructose (Fig. 1a and Supple-
mentary Fig. S1; [15]). Moreover, as this bacterium lacks phospho-
fructokinase, FBP can be produced exclusively only either an
upward reaction of trioses back to their cognate hexose, or by
phosphorylation of fructose 1-P by FruK (Fig. 1a). Structural, bio-
chemical and biophysical studies have revealed that the Cra pro-
tein ortholog of P. putida strain KT2440 (CraPP; 74% similarity and
48% identity with the CraEC; [16]) regulates the fruBKA operon
(Fig. 1b) encoding the fructose phosphotransferase system PTSFru
[16,17] and also that F1P is its preferred metabolic effector [16].
Speciﬁcally, electrophoretic mobility shift assays (EMSA) showed
that as little as 1 lM of F1P prevented binding of puriﬁed CraPP
to the PfruB promoter DNA. In contrast no effects on the CraPP-
DNA complex were brought about by any other metabolite tested
at the concentrations up to 1 mM. Isothermal titration calorimetry
(ITC) experiments with the same protein revealed also that F1P
binding to CraPP occurs with a 1:1 stoichiometry and a very high
afﬁnity (KD 200 nM). But consistently with the EMSA
experiments, neither FBP nor glucose-6-phosphate (G6P)
generated any ITC signal when mixed with CraPP [16]. Finally,
while diffracting CraPP-F1P co-crystals are easy to produce, it has
not been possible thus far to generate CraPP-FBP counterparts.
Taken together, the data above suggest that there is no interaction
of FBP with the CraPP protein, at least at effector concentrationsFig. 1. Metabolic regulation of the fructose operon of P. putida. (a) Generation of F1P an
from extracellular fructose, which enters the cell through the PTSFru system (FruBA). FBP i
glucose or succinate the lack of phosphofructokinase [15] makes FBP to be produced e
transformations are indicated (see Supplementary Fig. S1 for an expanded metabolic map
genes and the PfruB promoter containing one Cra operator (the quasi-palindromic 50TTAAA
binding to PfruB, the role of FBP is less clear. Numbers ﬂanking the operon indicate the g61 mM. Still, the literature reports that intracellular pools of FBP
and other glycolytic intermediates can go in bacteria up to
>15 mM under some physiological conditions [18]. Therefore, the
published experiments do not altogether rule out that other com-
pounds can also be physiological effectors of CraPP.
In view of the uncertainly on the role of FBP as agonist of CraPP
we set out to clarify unequivocally the nature of the metabolic sig-
nal that lets this regulator to detach in vivo from its genomic bind-
ing sites. By using a suite of biochemical, computational and
genetic approaches we show that no metabolite other than F1P
may act as an effector of CraPP. Since F1P is generated in P. putida
exclusively from exogenously added fructose, we argue that CraPP
is the main transducer of the presence of this sugar in the medium
into up/down downregulation of a large number of genes, whether
directly (i.e., via interaction with genomic CraPP-binding sites) or
indirectly through the action of proteins of the PTSFru system
encoded by fruBKA.
2. Results and discussion
2.1. Binding of CraPP protein to DNA fragments containing single and
double operators
The conditions of reference for examining the inﬂuence of
various glycolytic intermediates in the attachment of CraPP to its
genomic operators [16] is shown in Fig. 2a. The test involves 3
components: the CraPP protein puriﬁed to homogeneity [16], a
290 bp radioactively labeled DNA fragment spanning the single
operator for the regulator found in the PfruB promoter (Fig. 1b;
[16,17]) and F1P as an effector. Consistently with previous data
(i) as little as 50 nM protein sufﬁces to bind 100% of the targetd FBP upon entry of hexoses in the metabolic network of P. putida. F1P is produced
s generated also from fructose by phosphorylation of F1P by FruK. When growing on
xclusively through a back reaction of trioses into hexoses. Relevant enzymes and
). (b) Regulatory region of the fruBKA operon of P. putida. Note the organization of the
CGTTTCA30 sequence in red). While F1P de-represses the promoter by releasing Cra
enomic coordinates of the fruR fruBKA operon of P. putida KT2440.
Fig. 2. Interactions of the Cra protein of P. putida with its target region of the
fructose operon in response to various metabolic effectors. (a) Retardation assay
with increasing concentrations of Cra in the absence or presence of F1P 1 mM. Lane
1: Control free DNA probe containing the PfruB promoter of P. putida, which has one
single Cra operator (Fig. 1b). Lanes 2–7: 5 to 500 nM of Cra protein-only, no effector.
Lane 8: DNA probe in the presence of 1 mM F1P, no protein (control, C). Lanes 9–14:
5 to 500 nM of Cra protein with 1 mM F1P. (b) Retardation assay with 50 nM of Cra
and different candidate effectors. Lane 1: free DNA probe, no protein (control, C).
Lane 2: 50 nM Cra only, no effectors (Ref). Lane 3: 50 nM Cra protein and 1 mM F1P.
Lanes 4–7: 50 nM Cra protein and 1–15 mM FBP. Lane 8: 50 nM Cra protein and
1 mM F1P. Lanes 9–12: 50 nM Cra protein 50 nM and 1–15 mM of G6P. Gel
experiments were performed as indicated in the Section 4.
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most of the DNA-CraPP complex and impedes such a complete
binding to occur in vitro, even at the highest concentrations of
the regulator. The data of Fig. 2a is also consistent with the binding
to one single-site operator, as present in the DNA probe employed,
at least through CraPP levels 5–500 nM. Given the extraordinary
sensitivity of the EMSA test, we used the same setup for examining
the potential of other glycolytic intermediates i.e., FBP and G6P to
act also as agonists of the same regulator. To this end we repeated
the conditions of the experiment of Fig. 2a but using mM concen-
trations of each of the candidate effectors. Note that the binding
mixtures contain 50 nM of puriﬁed His6-CraPP [16], 0.05 nM of
the labeled DNA fragment and 1–15 mM of each potential agonist
(Fig. 2b). Therefore the effectors are in large molar excess, up to
3  105-fold. The gel of Fig. 2b shows that while FBP had no detect-
able effect on the stability of the CraPP-DNA interaction, G6P was
able to partially dissociate the complex at its highest concentra-
tions i.e., P10–15 mM. A third glycolytic intermediate, fructose-
6-P (F6P) was tested as well, but we did not observe any effect in
the stability of the CraPP-DNA interaction even when added to
the binding reaction at the highest concentration (not shown).
Although the results of Fig. 2 were observed at very high effec-
tor levels, they do open the possibility that F1P could not be the
only CraPP agonist. Since increasing further the concentrations of
CraPP, FBP or G6P in the assays for verifying such a possible out-
come would make little physiological sense we resorted to a differ-
ent strategy for amplifying the sensitivity of the binding assay. To
this end, we employed a DNA sequence containing two operatorsfor Cra instead of the one used before. The rationale of this choice
is that one can expand the effector sensitivity of a regulatory
device by changing the afﬁnity of the cognate transcription factor
(TF) for DNA rather than altering the effector-protein interaction
proper. In this way, a residual responsiveness of the TF to an effec-
tor becomes well detectable if the afﬁnity for the target operator is
artiﬁcially enhanced [19]. In our case, the alternative probe is a
290 bp DNA fragment corresponding to the regulatory region of
fructose operon of E. coli (Supplementary Fig. S2) which is
known to contain two site (O1 50TGAAACGTTTCA30; O2 50TGAA
TCGTTTCA30) that are cooperatively bound by the regulator [11].
Fig. 3a shows how the CraPP protein interacts with such a target
DNA with two binding sites and the disrupting effect of adding
F1P. The two retarded bands that show in the gel are explained
as the result of CraPP binding to either one (complex I) or both
operators (complex II) in the labeled DNA probe. When the EMSAs
were repeated with high FBP and G6P concentrations (Fig. 3b), the
results indicated much more clearly than in the case of the single-
operator probe (cf. Fig. 2b) that both glycolytic intermediates could
revert the protein-DNA interactions. These results are compatible
with earlier observations by Ramseier et al. [11] in that the
transcriptional repression caused by CraEC can be relieved in vitro
by P5 mM FBP. Still, as these effector concentrations are at the
upper limit and beyond those reported in the literature [18] there
is a legitimate doubt of whether the action of FBP on CraPP binding
to DNA reﬂects a genuine, speciﬁc regulatory occurrence. Alterna-
tively, they could be the result of using artifactually high effector
concentrations that lead to non-reliable effects. The in vitro and
in vivo experiments below were designed to shed light on this
outstanding question.
2.2. Interactions of CraPP with FBP and G6P are unspeciﬁc
In order to shed light on the nature of Cra effector(s), the inter-
action parameters of puriﬁed CraPP with the two principal candi-
date metabolites were examined by means of isothermal titration
microcalorimetry (ITC) as explained in the Methods section. The
benchmark for these tests was the ITC signals brought about by
the interaction of the same CraPP used in the EMSA experiments
with the bona ﬁde effector F1P. Prior to microcalorimetric assays
of the protein a number of buffer titrations were carried out to
identify the maximal concentration of a compound that give rise
to acceptable dilution heats. For the compounds studied, such con-
centration was found to be 1 mM. The reference titration of Cra
with F1P under such conditions is shown in Fig. 4b (equivalent
to ITC curve I in Fig. 4c). This control reproduced faithfully the
results reported in [16]: F1P binding to CraPP caused favourable
enthalpy changes, the effector-protein complex had an apparent
stoichiometry of one F1P/monomer, and the KD 200 nM. When
this experiment was repeated with FBP or G6P heat changes were
identical to the buffer titration with this ligand, indicating an
absence of binding (curves I of Fig. 4a and b). Note that under
the experimental conditions used the ﬁnal ligand concentration
in the cell was of 175 lM, which implies that a low-afﬁnity inter-
action cannot be detected. Increasing the concentration of the
ligand was not possible due to large dilution heats at the concen-
trations above 1 mM for all metabolites studied. To visualize a
potential low-afﬁnity interaction between FBP and Cra, an alterna-
tive strategy was chosen in which a mixture of 12 lM CraPP with
5 mM of FBP was titrated with a mixture of 0.45 lM F1P in
5 mM FBP. If FBP bound to Cra with an afﬁnity in the lower mM
range, the presence of this ligand at Cra would alter the thermody-
namic parameters of F1P as mentioned above (Fig. 4b). However,
this was not the case because the titration pattern of the CraPP-
FBP mixture with F1P (curve II in Fig. 4c) revealed thermodynamic
parameters close to the titration of CraPP with F1P-only (ITC curve I
Fig. 3. Binding of the Cra protein of P. putida to a target DNA containing two
cooperative sites. (a) Retardation assay with increasing concentrations of Cra in the
absence or presence of F1P 1 mM. Lane 1: Control free DNA probe containing the
PfruB promoter of E. coli, which has two cooperative Cra-binding sites (Supplemen-
tary Fig. S2). Lanes 2–7: 5 to 500 nM of Cra protein-only, no effector. Lane 8: DNA
probe in the presence of 1 mM F1P, no protein (control, C). Lanes 9–14: 5 to 500 nM
of Cra protein with 1 mM F1P. (b) Retardation assay with 50 nM of Cra and different
candidate effectors. Lane 1: free DNA probe, no protein (control, C). Lane 2: 50 nM
Cra only, no effectors (Ref). Lane 3: 50 nM Cra protein and 1 mM F1P. Lanes 4–7:
50 nM Cra protein and 1–15 mM FBP. Lane 8: 50 nM Cra protein and 1 mM F1P.
Lanes 9–12: 50 nM Cra protein 50 nM and 1–15 mM of G6P.
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not bind FBP with afﬁnities in the lower milimolar range, thereby
indicating that the protein is highly selective for F1P. These data
are not entirely compatible with the evidence of Fig. 3 showing
that augmenting the sensitivity of CraPP binding to its DNA targets
allowed to see a clear effect of high concentrations of either FBP or
G6P in the stability of the complex. What could be the origin of
such a phenomenon? Since we were unable to come to a
conclusion with the biochemical approaches described above we
resorted to a super-sensitive in vivo biosensor system for
unequivocally determine the physiological effector(s) of the
protein at stake.
2.3. In vivo experiments designate F1P as the only physiological
effector of CraPP
In order to solve the conundrum above (i.e., CraPP responds to
high concentrations of FBP in EMSA experiments but speciﬁc inter-
actions are not detected with ITC) we recreated the regulatory sys-
tem in vivo with various genetic constructs. To this end we ﬁrst
transferred the low-copy number plasmid pMCH1 [17] to P. putida
KT2440. This plasmid carries a translational fusion fruB0-0lacZ
which allows the readout of CraPP binding in vivo to the promoter
of the fruBKA operon. In the absence of metabolic effectors, CraPP
binds strongly its operator in the region of the PfruB promoter
(Fig. 1) and represses production of b-galactosidase [16,17]. On
the contrary, when CraPP metabolic agonists release repression,
the lacZ fusion is transcribed and the reporter is expressed. In order
to measure accurately b-galactosidase we adopted a variant of theMiller assay [20] that uses the super-sensitive b-Galacto-Light
PlusTM luminiscent substrate of the enzyme [21].
Since P. putida cannot internalize phosphorylated sugars F1P/
FBP, these effectors could not be added directly to the medium
for examining their action in vivo. Instead, as the metabolic map
of P. putida KT2440 has been determined ([15,22,23]; Supplemen-
tary Fig. S1) we considered to manipulate intracellular levels of F1P
or FBP by growing the cells on distinct substrates. Signiﬁcant con-
centrations of F1P can be brought about by simply growing cells on
fructose, because this hexose becomes transformed instantly into
F1P upon transport through the PTSFru system (Fig. 1a; [17]). How-
ever, growth in the same sugar also leads to generation of low-mM
concentrations of FBP (1.3 mM, Fig. 5a), what makes interpreta-
tion of any fruB0-0lacZ induction result impossible. Therefore, we
attempted to increase the concentration of FBP, while keeping
F1P levels to the lowest achievable in vivo. Analysis of FBP in suc-
cinate-grown and glucose-grown cells revealed levels of this effec-
tor in the range 60 lM and 275 lM, respectively (Fig. 5a). Since,
according to the metabolic models of P. putida, F1P can only be
generated by fructose (Supplementary Fig. S1), any fruB0-0lacZ
activity of cells growth on either succinate or glucose should be
traced to the effect of FBP. Inspection of the results of Fig. 5b indi-
cated that the fruB0-0lacZ was strongly induced as expected in fruc-
tose-grown cells and not induced at all in succinate cultures. These
extreme values set the upper and the lower limits of activity of the
reporter fusion, as there was a plenty of an optimal inducer (F1P,
fructose) and very low concentrations of the candidate effector
(FBP, succinate). However in the presence of glucose reporter cells
nearly tripled the readout of b-galactosidase as compared to succi-
nate conditions (Fig. 5c). Since F1P cannot be formed under these
conditions, the result suggested that the levels of FBP detected in
these cells could induce the PfruB promoter and thus be an authen-
tic physiological effector of CraPP. The data shown in Fig. 6, how-
ever, ruled out altogether this possibility. In this case, we
repeated the same experiment with glucose but using a DfruB
mutant as the host of the fruB0-0lacZ reporter system. This strain
is unable to transport fructose and therefore cells exclude any pos-
sible trace of this sugar that may contaminate the glucose added to
the medium. When b-galactosidase was measured in the DfruB
strain, the differences between succinate and glucose altogether
disappeared (Fig. 6a). To ensure that the lack of fruB entirely
prevented the entry of fructose in the medium we run a control
experiment in which succinate-grown cells having or lacking a
functional fruB gene were added with growing concentrations of
fructose. As shown in Fig. 6c, as little as 10 lM fructose sufﬁced
multiply by 3-fold the levels of b-galactosidase of succinate-grown
wild-type cells. In contrast, the DfruB mutant kept very low the
activity of the reporter even at higher fructose concentrations.
Taken together, these results mean that (i) the levels of FBP that
P. putida cell may accumulate are not sufﬁcient to de-repress the
PfruB promoter, (ii) FBP is not a physiological effector of the CraPP
protein and (iii) the residual expression of fruB0-0lacZ in glucose-
grown cells is due to a contamination of this sugar by traces of
fructose. Although the glucose employed in the experiments of
Figs. 5 and 6 has the maximum commercial purity (>99.5%,
SIGMA), this sugar can be partially converted to fructose in both
slightly acid and basic aqueous solutions [24]. The process begins
by the spontaneous opening of the hemiacetal ring to an open-
chain aldehyde, which undergoes keto-enol tautomerization to
its enediol form – which is shared by the two sugars. Subsequent
tautomerization to different keto forms produces open-chain fruc-
tose, the cyclization of which completes the process. On this basis,
it has been calculated that >1% of glucose can tautomerize to
fructose [25]. Such traces of fructose would sufﬁce to explain the
induction of fruB0-0lacZ in glucose-grown cells – while clarifying
the conundrum of FBP as a non-agonist of CraPP. We cannot rule
Fig. 4. ITC assays with Cra and effectors. The upper panels plot raw data from representative ITC experiments, whereas the lower panels show the ﬁtted curves of the same
results but integrated and corrected for dilution. (a) Titration of dialysis buffer (I) and 12 lM of Cra (II) with 14.4 ll aliquots of 1 mM FBP. (b) Titration of dialysis buffer (I) and
12 lM of Cra (II) with 14.4 ll aliquots of 1 mM G6P. (III) corresponds to positive control. i.e., titration of 12 lM of Cra with 3.2 ll aliquots of 0.5 mM of F1P. (c) ITC competition
experiments were performed by titration of 12 lM Cra containing 5 mM FBP with 4.8 ll of a mixture of 0.45 lM F1P and 5 mM FBP (II and ﬁlled circles in the bottom panel).
The ﬁgure also shows the titration of 12 lM Cra with 4.8 ll aliquots of 0.5 mM F1P (I, and empty circles in the bottom panel). The bottom panel corresponds to the
superposition of the titration curves of the experiments mentioned above, which are virtually identical, suggesting that FBP does not bind to CraPP. Note that only the titration
with F1P produces a heat change in the experiment at the tested concentrations. Negative peaks are indicative of an exothermic event.
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in vitro (Figs. 2 and 3) could be due to traces of F1P in the
corresponding preparations.
The results above on the exclusivity of F1P as the physiological
Cra effector raise the issue of their generalization to bacteria other
than P. putida. While in this species the TF seems to have special-
ized in controlling fructose uptake, the orthologs in other bacteria
(in particular, E. coli) have been found to respond to both F1P and
FBP and behave as sensors of the glycolytic ﬂux [13]. In order to
identify the structural basis for such functional divergence in
otherwise very similar proteins, we resorted, to molecular model-
ing for comparing the interaction details of the CraPP and its
enterobacterial counterpart (i.e., the E. coli protein CraEC) with their
effectors F1P and FBP.
2.4. Molecular docking exposes the exclusivity of F1P as the metabolic
effector of CraPP
In order to analyze the binding potential of F1P and FBP to CraPP
we performed separate docking of these metabolites into the X-ray
structure of the regulator available in the RSCB PDB database using
as a reference the counterpart TF from E. coli. Since the crystal
structures included the two monomers of the functional protein
(chain A and chain B; [16]) the molecular docking was performed
separately into either of them (Fig. 7). We ﬁrst addressed the dock-
ing of CraPP complexed with F1P (PDB: 3O75; [16]), which revealed
19 possible favorable binding modes to the chain A and 20 to the
chain B (Supplementary Table S1). For each chain, the predicted
binding types that matched experimentally the way of interaction
with F1P were found to rank the ﬁrst and the second by their low-
est binding energies and were the most prevalent among all calcu-
lated binding modes (40.4% and 37.6%). When the same structure
(PDB: 3O75) was tested for FBP binding, the docking identiﬁed
26 binding modes to the chain A and 24 to the chain B (Supplemen-
tary Table S2). While the simulated binding modes of FBP to either
chain ranked the ﬁrst and the third by their lowest energies, theiroccurrences (15.2% and 10.4%, respectively) were far less frequent
in comparison to F1P. We then explored binding of the same effec-
tors to the effector-free crystal structure of CraPP (PDB: 3O74; [16]),
what resulted in 13 possible binding modes to the chain A and 17
to the chain B (Table S3). The simulations of binding energies in
this case ranked very closed to those derived from the 3O75 struc-
ture, but the occurrences of each binding mode to effector-free
CraPP were less frequent (8.4% and 7.6% to the chain A and B,
respectively), thereby indicating a probable conformational adap-
tation of Cra induced upon F1P binding. Docking of FBP into the
3O74 structure resulted in 20 possible binding modes to the chain
A and 19 to the chain B (Supplementary Table S4). These modes
ranked the second and the sixth by their lowest binding energies,
but, as above, their occurrences (13.2% to the chain A and 8.4% to
the chain B) changed only slightly in comparison with the results
obtained for 3O75 structure. Finally, we simulated the binding of
F1P and FBP to the effector-free crystal structure of the protein
of E. coli (PDB: 2IKS, unpublished). In one case, docking of F1P into
2IKS resulted in 47 binding modes to the chain A and 46 to the
chain B (Supplementary Table S5), which possessed the seventh
and the thirty-ﬁrst lowest binding energies. The same with FBP
yield 73 possible binding modes to the chain A and 58 to the chain
B (Supplementary Table S6), ranking the thirty-sixth and the
thirty-seventh by their binding energies. Interestingly, the binding
occurrences of both F1P (3.2% and 0.4% to the chain A and B) and
FBP (0.8% and 0.4%) to CraEC were quite rare in comparison to CraPP.
Table 1 shows the overview for the molecular docking results of
F1P and FBP into the three different crystal Cra structures averaged
over the two polypeptide chains. The data indicate that (i) binding
of either effector into the binding site of any of the Cra variants
tested is thermodynamically favored and (ii) F1P is always pre-
ferred over FBP irrespective of the Cra type. While the difference
between the energy released by of F1P and FBP binding to CraPP
was as high as 2 kcal/mol, the breach decreased by half
(1 kcal/mol) in the case of to CraEC. This accounts for the extraor-
dinary selectivity of CraPP for F1P (KD = 209 ± 20 nM) as compared
Fig. 5. Metabolic control of PfruB activity. (a) FBP levels in P. putida growing on glycolytic (fructose and glucose) and gluconeogenic (succinate) substrates. Wild-type cells of P.
putida KT2440 were grown in M9 media with the substrate indicated until the mid-exponential phase and then processed for measuring FBP levels by HPLC-MS as described
in the Section 4. The data shown correspond to three independent samples, the error bars representing the standard deviations of the mean. (b) PfruB activity in cells grown on
succinate, glucose and fructose as the sole C source. A schematic diagram of the fruB0-0lacZ gene fusion borne by reporter plasmid pMCH1 is sketched on top. Note the very
high activity in cells grown on fructose in contrast with those in succinate or glucose. (c) Blowup of lacZ readout of P. putida (pMCH1) cells growing on succinate or glucose.
Fig. 6. Effect of DfruB on the activity of a fruB0-0lacZ fusion. PfruB activity in P. putida (pMCH1) cells lacking the fruB gene growing in (a) glucose with increasing concentrations
(10 and 100 lM) of fructose and (b) succinate with increasing concentrations (10 and 100 lM) of fructose. (c) PfruB activity in wild type cells grown with succinate plus
fructose. b-Galactosidase activity was measured with Galacton-Plus as described in the Section 4. Note that lacZ levels of the DfruB strain remain unchanged regardless of
succinate or glucose, plausibly due to the inability of cells to internalize fructose and thus generate F1P.
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is further supported by signiﬁcantly larger number of possible
binding modes of both docked effectors as well as lower probability
of their calculated binding modes.
2.5. Molecular dynamics of F1P and FBP bound to CraPP
To gain a further insight on the selectivity of CraPP for its
physiological effector we run simulations of the interactions of
F1P and FBP bound to the CraPP structure (PDB: 3O75) and the
CraEC (PDB: 2IKS). Once reaching a constant temperature, the
dynamically simulated systems were found to be equilibrated
based on the stable values of energies, density, gyration radius
and the mean root square deviation of protein backbone atoms,
over the entire length of the production molecular dynamics
simulation (data not show). The binding free energy calculated
by MM-PBSA and the normal mode analysis for all four investi-
gated complexes are shown in Supplementary Table S7. In goodagreement with the data of docking calculations presented above,
the favorable free binding energies conﬁrm that both F1P and FBP
can bind to either Cra variant. However, the divergence between
the free binding energy of F1P and FBP (Supplementary Table S7)
is signiﬁcantly larger in the case of CraPP (7.2 ± 2.5 kcal/mol) than
E. coli’s CraEC (3.8 ± 1.1 kcal/mol). Such differences imply a differ-
ence of six orders of magnitude in the afﬁnity of CraPP for each of
the effectors as compared to the 3 orders of magnitude in the case
of CraEC. These analyses both account for the extreme selectivity of
CraPP towards F1P and explain why the E. coli’s protein has, other-
wise, a broader effector range in vivo that reaches out physiological
ﬂuctuations of FBP [13].
3. Conclusions
Inspection of the crystal structure of CraPP [16] along with the
suite of biochemical and biophysical tests presented in this work
reveal without a doubt, that F1P is the one and only metabolic
Fig. 7. Binding modes of F1P and FBP exposed by molecular docking of the effector molecules to the crystal structures of CraPP and CraEC. Predicted binding modes of F1P
(cyan sticks) and FBP (yellow sticks) obtained from docking into (a) chain A of CraPP complexed with F1P (structure PDB: 3O75), (b) chain A of effector-free CraPP (structure
PDB: 3O74), (c) chain A of effector-free CraEC (structure PDB: 2IKS), (d) chain B of CraPP complexed with F1P (structure PDB: 3O75), (e) chain B of effector-free CraPP (structure
PDB: 3O74) and (f) chain B of effector-free CraEC (structure PDB: 2IKS). The experimentally determined conformation of F1P is shown with green sticks and the protein
structures with green lines.
Table 1
Properties of the calculated binding modes of metabolic effectors averaged over both
Cra protein chains.
Effector Cra structure Mean docked
energy (kcal/mol)
Occurrence of
binding mode (%)
F1P 3O75 8.29 39
3O74 7.40 8
2IKS 5.65 2
FBP 3O75 6.45 13
3O74 5.35 11
2IKS 4.72 1
F1P, fructose 1-phosphate; FBP, fructose 1,6-bisphosphate; 2IKS, effector-free CraEC;
3O74, effector-free CraPP; 3O75, CraPP complexed with F1P.
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This is in contrast with the situation for the enterobacterial coun-
terpart where FBP is one of the physiological agonists of the regu-
lator. Since FBP is a key metabolite of the standard Ebmden–
Meyerhoff–Parnas (EMP) pathway, its levels are considered a proxy
of the glycolytic course and CraEC a ﬂux sensor [13]. In contrast, P.
putida lacks the EMP route and intracellular FBP concentrations are
not sufﬁcient to elicit de-repression of the PfruB promoter.
Moreover, according to current metabolic models for this
microorganism, F1P is formed in vivo only as a result of fructose
phosphorylation by the PTSFru system (Supplementary Fig. S1;
[15,17]). Since the P. putida’s genome containsP50 Cra boxes with
the potential to control a suite of cellular functions (Supplemen-
tary Table S8), we suggest that fructose is an important environ-
mental signal for this bacterium beyond its mere status of being
a C source, an issue that deserves further studies. In any case, it
seems clear that Cra (i) is used in different bacteria for sensing dis-
similar physiological conditions and that (ii) such functional re-
assignment can be brought about by subtle modiﬁcations of its
binding parameters to possible effectors. In our case, it is likely that
otherwise orthologous Cra versions have been co-opted in different
hosts to regulate target genes in response to unlike metabolic
inputs. Such a regulatory exaptation [26] thus provides a rationale
of how both TFs and their cognate regulons can dramatically
diversify in different bacteria.
4. Materials and methods
4.1. Bacterial strains, plasmids, culture media, and growth conditions
All P. putida strains were derived from P. putida KT2440 [27].
DfruB strain was reported previously [17] and was constructed
using de protocol described by Martínez-García et al. [28]. P. putida
and E. coli strains were cultured at 30 C and 37 C, respectively, in
an aerated orbital shaker at 170 rpm. The rich medium used to
grow all strains of this study was Luria-Bertani (LB; [29]). Whereindicated, P. putida strains were also cultured in minimal medium
M9 [20], supplemented with 0.2% (w/v) fructose, glucose or succi-
nate as the sole carbon and energy source added, if necessary with
50 lg/ml kanamycin (Km). Broad host range pMCH1 plasmid con-
taining a PfruB? fruB0-0lacZ reporter translational fusion has been
described previously [17]. Both plasmids were separately trans-
formed in P. putida KT2440 and its DfruB variant [17] as required.
4.2. Measurements of b-galactosidase activity
The extremely sensitive Galacton-Light PlusTM system (Applied
Biosystems) was employed for measuring b-galactosidase levels in
lacZ+ P. putida cells. To this end, each strain under examination was
pregrown in M9 with glucose or succinate in presence of Km to
ensure retention of the reporter plasmids and then diluted to an
OD600 0.05. Once bacteria had reached OD600 0.3–0.6, the cells
of 0.5 ml of each culture were spun down (2 min, 14,000g) and
the pellet resuspended in 200 ll of lysis buffer (100 mM potassium
phosphate pH 7.8, 0.2% Triton X-100). The mixtures were subjected
to two freeze-thaw cycles in liquid nitrogen and clariﬁed by centri-
fugation 1 min at 14,000g. 20 ll of the supernatant were then
deposited in the wells of microtiter plates, added with 80 ll of
reaction buffer (100 mM sodium phosphate, pH 8.0, 1 mM MgCl2,
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added with 125 ll of Accelerator-II Sapphire-II™ and light emis-
sion recorded for 30 s in a luminometer following the instructions
of the commercial supplier. All the enzymatic measurements pre-
sented through this paper are the result of at least six biological
replicates.
4.3. Gel retardation assays
The PfruBPP probe used for these tests containing a single Cra bind-
ing site was ampliﬁed from plasmid pMCH1 with oligonucleotides
50PfruB (50CGAATTTTCCTTGTTATTACCGGG30) and 30PfruB (50CGGA
ATTCGACCTTCTCCTTTTGCAGTTCCC30, an engineered EcoRI site is
underlined). The equivalent PfruBEC probe with two Cra binding sites
was similarly ampliﬁed from the puriﬁed genomic DNA of E. coli
W3110 by using oligonucleotides 50PfruBcoli (50 CTGA TA ACG
GATTTTCCCATCAGC30) and 30PfruBcoli (50CGGAATTCGCCTCTT
CTTTGTCTCCGGCC30; the EcoRI site underlined). In both cases,
the ampliﬁed DNA was digested with EcoRI and the resulting
290 bp fragments were 30-end labelled by ﬁlling-in the EcoRI-
digested overhanging end of the fragment with [a-32P]dATP and
the Klenow fragment of E. coli DNA polymerase as reported previ-
ously [30]. The retardation reactions were set in TRRG buffer
(20 mM Tris/HCl, pH 7.5, 10% glycerol, 2 mM b-mercaptoethanol
and 50 mM KCl) and contained 0.05 nM DNA probe, 250 lg/ml
BSA, 50 nM puriﬁed His6-Cra protein (produced as described in
[16]) and concentrations 1–15 mM of effectors in a ﬁnal volume
of 9 ll. After incubation of the retardation mixtures for 20 min at
room temperature, the mixtures were analyzed by electrophoresis
in 5% polyacrylamide gels buffered with 0.5X TBE (45 mM Tris/
borate, 1 mM EDTA). The gels were dried on Whatman 3MM paper
and exposed to X-Ray Film (Konica Minolta).
4.4. Isothermal titration microcalorimetry (ITC)
ITC experiments were performed on a VP microcalorimeter
(MicroCal, Northampton, MA, USA) at 25 C. Prior to experiments,
Cra was thoroughly dialyzed in 25 mM Tris-HCl, 50 mM NaCl,
1 mM DTT, pH 8.0. After the protein solution was then clariﬁed
trough a 0.45 lm ﬁlter and its concentration was determined by
UV absorption spectroscopy using and extinction coefﬁcient of
1.217  105 cm1 M1 at 280 nm [31]. Effectors were prepared by
diluting pure powdered products in ﬁltered dialysis buffer so that
the ligand and protein solvent were the same. Titration with F1P
(positive control) involved 4.8 ll injections of 0.5 mM F1P into a
12 lM protein solution. On the other hand, titration with FBP
and G6P involved 14.4 ll injections of 1 mM FBP (or G6P) into a
12 lM protein solution. For competition experiments a mixture
of 5 mM of FBP with 12 lM of Cra protein was titrated with a mix-
ture of 0.45 lM of F1P and 5 mM of FBP. For all the experiments,
the mean enthalpies measured from injection of the ligands into
the buffer were subtracted from raw titration data prior to data ﬁt-
ting using the One binding site model of the MicroCal version of the
ORIGIN software. From the curves thus ﬁtted, the parameters DH
(reaction enthalpy), KA (binding constant, KA = 1/KD), and n (reac-
tion stoichiometry) were determined. From the values of KA and
DH, the change in free energy (DG) and in entropy (DS) were cal-
culated with the equation: DG = RT lnKA = DH  TDS, where R is
the universal molar gas constant and T is the absolute temperature.
4.5. Determination of FBP concentrations by liquid chromatography
mass spectrometry
For quantiﬁcation of FBP, P. putida KT2440 were pregrown in
M9 medium with 0.2% (w/v) fructose, glucose or succinate as
required and then re-inoculated in the same media to a startingOD600 = 0.05. Cultures were then let grow until exponential phase,
at which point the biomass corresponding to 0.5–0.6 mg of cellular
dry weight (CDW, 4 ml of culture to OD600 0.5–0.6) of triplicate
samples was collected by fast centrifugation (13,000g, 30 sec)
and the bacterial pellets immediately frozen in liquid nitrogen
until further processing. At that point, samples were extracted
three times with 0.5 ml 60% (v/v) ethanol buffered with 10 mM
ammonium acetate pH 7.2 at 78 C for 1 min as described previ-
ously [32,33]. After each extraction step, biomass was separated
by centrifugation for 1 min at 13,000g. The three liquid extracts
of each sample were pooled prior to drying at 120 lbar to com-
plete dryness and then stored at 80 C. Samples were then resus-
pended in 20 ll of MilliQ water, sealed in 96-well plates, submitted
to LC-MS and the data analyzed as described previously [33].
4.6. Molecular docking calculations
The molecular models of F1P and FBP were prepared and
energy-minimized in the Avogadro 1.0.2 package [34]. The proce-
dure involved 500 steps of steepest descent followed by 500 steps
of conjugate gradient using the GAFF force ﬁeld [35]. The crystal
structures were downloaded from RSCB PDB database under fol-
lowing PDB codes: 2IKS (effector-free Cra from E. coli), 3O74 (effec-
tor-free Cra from P. putida), and 3O75 (Cra from P. putida
complexed with F1P). All crystallographic water molecules were
removed and hydrogen atoms were added to the proteins by H++
server at pH 8.0 using the default settings [36]. Gasteiger charges
and AutoDock 4.2 atom types were assigned to protein and ligand
structures by MGLTools [37]. During docking procedure, the recep-
tor binding site was represented by the set of atomic and electro-
static grid maps calculated by AutoGrid 4.2 [38,39]. Individual
chains of Cra structures were aligned to the chain A of 3O74 struc-
ture using Pymol 1.4.1 (http://pymol-molecular-graphics-sys-
tem.soft112.com) and the grid maps were set to 80  80  80
grid points with spacing 0.25 Å centered at the position of C2 atom
of F1P bound to chain A of 3O75. This setting of the grid maps
allows full coverage of Cra binding site. Both ligands were then
docked separately into the binding sites of each chain of all struc-
tures using AutoDock 4.2 [38,39]. 250 docking calculations were
performed for each ligand employing the Lamarckian Genetic algo-
rithm with the following parameters: initial population size 300,
maximum of 30,000 generations, elitism value 1, mutation rate
0.02, and cross-over rate 0.8. The maximum of energy evaluations
were set to 10,000,000. The local search was based on pseudo Solis
and Wets algorithm with a maximum of 300 iterations per local
search [40]. Energy of unbound system was estimated as the inter-
nal energy of the unbound extended conformation determined
from Lamarckian Genetic Algorithm search. Final orientations from
every docking run were clustered with a clustering tolerance for
the root-mean-square positional deviation of 1.5 Å.
4.7. Molecular dynamics simulations
The F1P-3O75, FBP-3O75, F1P-2IKS and FBP-2IKS complexes
obtained by the molecular docking were used as the initial struc-
tures for the molecular dynamics simulations. Crystallographic
waters were put back to their original positions with the exception
of water molecules overlapping with the docked effectors. AM1-
BCC atomic partial charges [41] and the force ﬁeld parameters
for F1P and FBP were generated with the Antechamber module
of AMBER11 [42,43] using the total charges of 2 e and 4 e for
F1P and FBP, respectively. Using Tleap module of AMBER11, the
systems were neutralized by adding 8, 10, 16 and 18 Na+ ions to
F1P-3O75, FBP-3O75, F1P-2IKS and FBP-2IKS complexes, respec-
tively. Using the same module, an octahedral of TIP3P water mol-
ecules [44] was added to the distance of 10 Å from any solute
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ics simulations were carried out in PMEMD module of AMBER11
using ff99SB force ﬁeld [45] for a protein and GAFF force ﬁeld
[35] for the ligands. Initially, the investigated systems were
minimized by 500 steps of steepest descent followed by 500
steps of conjugate gradient in ﬁve rounds of decreasing
harmonic restraints. The restraints were applied as follows:
500 kcal mol1 Å2 on all heavy atoms of a protein, and then 500,
125, 25 and 0 kcal mol1 Å2 on the backbone atoms only.
Molecular dynamics simulations employed periodic boundary
conditions, the particle mesh Ewald method for treatment of the
electrostatic interactions [46,47], 10 Å cutoff for nonbonded
interactions, and 2 ft time step with the SHAKE algorithm to ﬁx
all bonds containing hydrogens [48]. Equilibration simulations
consisted of two steps: (i) 20 ps of gradual heating from 0 to
300 K under constant volume, using a Langevin thermostat with
collision frequency of 1.0 ps1, and with harmonic restraints of
5.0 kcal mol1 Å2 on the position of all protein and effector atoms,
and (ii) 2000 ps of unrestrained molecular dynamics at 300 K using
the Langevin thermostat, and constant pressure of 1.0 bar using
pressure coupling constant of 1.0 ps. Finally, production molecular
dynamics simulations were run for 10 ns with the same settings as
the second step of equilibration simulations. Coordinates were
saved in 1 ps interval, and the trajectories were analyzed using
Ptraj module of AMBER11, and visualized in Pymol 1.4.1 (see
above) and VMD 1.8.9 [49].
4.8. Calculation of the binding free energy
The free energy for the binding of potential effectors to the indi-
vidual proteins was calculated by the Molecular Mechanics/Pois-
son Boltzmann Surface Area (MM-PBSA) method using
MMPBSA.py script of AMBER11 [50]. The polar solvation free energy
contributions were determined by grid based ﬁnite-difference
solution of the Possion–Boltzmann equation using pbsa [51] pro-
gram of AMBER11 The setting of the Possion–Boltzmann calcula-
tions were following: ionic strength of 75 mM, grid spacing of
0.5 Å, the internal and external dielectric constants of 1 and 80,
respectively, and modiﬁed Bondi radii [52] for ligands. The nonpo-
lar solvation free energy contribution was estimated as propor-
tional to the solvent accessible surface area using the LCPO
method [53]. The entropy change upon effector binding was eval-
uated using the normal-mode analysis implemented in NAB mod-
ule of AMBER11 using distance-dependent dielectric of 4rij. The
energy was calculated over 10,000 snapshots extracted from a sin-
gle production molecular dynamics simulation of a complex, and
the entropy contribution was calculated from 100 snapshots
evenly sampled from the snapshots employed in the energy
calculation.
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